Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 4, 2006, Pages 709-713

  Rodés, Berta ^a   Sheldon, Julie ^a   Toro, Carlos ^a   Jiménez, Victoria ^a   Álvarez, Miguel Ángel ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HAART; Resistance; Retroviruses

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; TREATMENT FAILURE; VIRUS ISOLATION; WILD TYPE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PHENOTYPE; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 33645121140     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl034     Document Type: Article

References (30)

1. Marlink R, Kanki PJ, Thior I et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265: 1587-90.
2. Matheron S, Pueyo S, Damond F et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS 2003; 17: 2593-601.
3. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83: 1253-65.
4. Ren J, Bird LE, Chamberlain PP et al. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA 2002; 99: 14410-15.
5. Witvrouw M, Pannecouque C, Switzer W et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9: 57-65.
6. Tuaillon E, Gueudin M, Lemée V et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004; 37: 1543-9.
7. Adje-Toure C, Cheingsong R, Garcia-Lerma J et al. Antiretroviral therapy in HIV-2-infected patients: Changes in plasma viral load,CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Coôte d'Ivoire. AIDS 2003; 17: S49-54.
8. Mullins C, Eisen G, Popper S et al. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004; 38: 1771-9.
9. Weusten JJAM, Carpay WM, Oosterlaken TAM et al. Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res 2002; 30: E26.
10. Rodes B, Toro C, Jimenez V et al. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin Infect Dis 2005; 41: E19-21.
11. Rodes B, Holguin A, Soriano V et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38: 1370-4.
12. Johnson V, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13: 51-7.
13. Vandamme A, Witvrouw M,Pannecouque C et al. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Kirchington D, Schinazi R, eds. Antiviral Methods and Protocols. New Jersey: Humana Press, 2000; 223-58.
14. Paolucci S, Baldanti F, Zavattoni M et al. Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. J Antimicrob Chemother 2003; 51: 135-9.
15. Gonzalez LMF, Brindeiro RM, Tarin M et al. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003; 47: 2817-22.
16. Rusconi S, La Seta Catamancio S, Citterio P et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44: 1328-32.
17. Colson P, Henry M, Tourres C et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004; 42: 570-7.
18. Damond F, Brun-Vezinet F, Matheron S et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol 2005; 43: 484-7.
19. Pieniazek D, Rayfield M, Hu D et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004; 18: 495-502.
20. Ohtaka H, Schön A, Freire E. Multidrug resistance to HIV-1 protease inhibitor requires cooperative coupling between distal mutations. Biochemistry 2003; 42: 13659-66.
21. Muzammil S, Ross P, Freire E. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 2003; 42: 631-8.
22. Weber J, Majer P, Litera J et al. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: Design of equipotent lead compounds. Arch Biochem Biophys 1997; 341: 62-9.
23. van der Ende M, Prins J, Brinkman K et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17: S55-61.
24. Swairjo M, Towler E, DebouckCet al. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease. Biochemistry 1998; 37: 10928-36.
25. Velazquez-Campoy A, Vega S, Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002; 41: 8613-19.
26. De Luca A, Vendittelli M, Baldini F et al. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. Antivir Ther 2004; 9: 583-93.
27. Carrillo A, Stewart KD, Sham HL et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72: 7532-41.
28. Friend J, Parkin N, Liegler T et al. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18: 1965-6.
29. Kagan RM, Shenderovich MD, Heseltine PNR et al. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci 2005; 1870-8.
30. Rodes B, Toro C, Sheldon J et al. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20: 127-9.